Spectranetics’ Stellarex 0.014-Inch DCB Approved in Europe

 

November 21, 2016—The Spectranetics Corporation announced that the company’s Stellarex 0.014-inch drug-coated balloon (DCB) has received European CE Mark approval.

The Stellarex 0.014-inch device is designed to treat small vessels, below-the-knee disease, and critical limb ischemia. The combination of the currently available Stellarex 0.035-inch and the new 0.014-inch option available in Europe expands Spectranetics’ portfolio of next-generation DCBs to treat complex disease states across the lower extremities, stated the company.

Prof. Dierk Scheinert, MD, of Universitätsklinikum in Leipzig, Germany, commented in Spectranetics’ announcement, “Now available on a 0.014-inch balloon platform, Stellarex represents a latest generation DCB backed by compelling evidence in the fem-pop arteries. It holds strong promise to deliver safety and efficacy in the notoriously challenging infrapopliteal district.”

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.